ILUVIEN Phase 4 Trial Hits Both Primary Endpoints in Chronic Uveitis
ANIP sits 32% above its 52-week low of $62.605.
Summary
The SYNCHRONICITY trial met both co-primary endpoints with statistical significance, showing a mean gain of 3.6 ETDRS letters in visual acuity and a 157.5-micron reduction in retinal thickness at 6 months. The safety profile was consistent with prior ILUVIEN studies, with manageable ocular hypertension and cataract rates. This data strengthens the clinical evidence for ILUVIEN in chronic non-infectious uveitis, a market where it already holds FDA approval since 2025. The positive results could drive broader adoption among retina specialists and support reimbursement discussions. Detailed analyses are expected at medical conferences in Q4 2026, which may provide further differentiation from competitors.
At the time of this announcement, ANIP was trading at $82.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $62.61 to $99.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.